title: Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.
abstract: OBJECTIVE
  The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted.
  
  
  METHODS
  We have retrospectively analyzed activity of rituximab (375 mg/m(2) i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m(2) i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL.
  
  
  RESULTS
  Patients had been heavily pretreated (median 3 prior therapies, range 1-9) and had stage III/IV disease. Nine out of 12 patients responded (75 %, 4 CR, 5 PR). Median progression-free survival was 9.3 months, and overall survival has not been reached. Adverse events greater than grade II included anemia (17 %) and thrombocytopenia (33 %).
  
  
  CONCLUSIONS
  R-ADOx is active and well tolerated in heavily pretreated MCL patients.
authors.affiliation: Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria, wolfgang.lamm@meduniwien.ac.at.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Lamm
authors.forename: Johannes
authors.initials: J
authors.lastname: Drach
authors.forename: Barbara
authors.initials: B
authors.lastname: Kiesewetter
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Zielinksi
authors.forename: Marius E
authors.initials: ME
authors.lastname: Mayerhöfer
authors.forename: Leonhard
authors.initials: L
authors.lastname: Müllauer
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D009944:Organoplatinum Compounds; D003561:Cytarabine; D000077150:Oxaliplatin; D000069283:Rituximab; D003907:Dexamethasone